Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045326 | 0.94 | REN (0.52) | REN | |
| SCHEMBL6044215 | 0.93 | REN (0.57) | REN | |
| SCHEMBL6044227 | 0.93 | REN (0.57) | REN | |
| SCHEMBL6044334 | 0.91 | REN (0.49) | REN | |
| SCHEMBL6044855 | 0.91 | REN (0.56) | REN | |
| SCHEMBL1596463 | 0.90 | REN (0.65) | REN | |
| SCHEMBL1596465 | 0.90 | REN (0.65) | REN | |
| SCHEMBL12990669 | 0.90 | REN (0.65) | REN | |
| SCHEMBL1596464 | 0.90 | REN (0.65) | REN | |
| SCHEMBL1133187 | 0.90 | REN (0.56) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689702-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-8198465-B2 | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG (CH) | 2012-06-12 | — | — | US | disclosed |
| US-8198465-B2 | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG (CH) | 2012-06-12 | — | — | US | disclosed |
| US-8143416-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143416-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20120022100-A1 | ORGANIC COMPOUNDS | MAIBAUM JUERGEN KLAUS (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20110137044-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20110137044-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-7919529-B2 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides | NOVARTIS AG (CH) | 2011-04-05 | — | — | US | disclosed |
| US-7919529-B2 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides | NOVARTIS AG (CH) | 2011-04-05 | — | — | US | disclosed |
| EP-1789377-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | Novartis AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007045420-A2 | 3-ALKYL-5- (4-ALKYL-5-OXO-TETRAHYDROFUTRAN-2-YL) PYRROLIDIN-2-ONE DERIVATIVES AS INTERMEDIATES IN THE SYNTHESIS OF RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-04-26 | — | — | WO | disclosed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2006024501-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024501-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2006-03-09 | — | — | WO | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022100-A1 | ORGANIC COMPOUNDS | AGTR1, AGTR2, REN | REN 3/4885 |
| US-20110137044-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | REN, ACE, AGT | REN 1/4885 |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | REN 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.